BIOMAT Database Logo BIOMAT Database Logo

Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. 1993

D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Liver Unit, Hadassah University Hospital, Jerusalem, Israel.

Pre- and postexposure prophylaxis against hepatitis A virus (HAV) infection with immune serum globulin (Ig) is only effective for 4-6 months. We compared the safety, tolerability and immunogenicity of a single i.m. injection of Ig with a single and booster dose of an inactivated hepatitis A virus vaccine (iHAV) in adults. Healthy volunteers (18-50 years) received a single Ig i.m. injection (n = 30), or iHAV i.m. (n = 15) at 0 and 24 weeks, or placebo (n = 4) at the same intervals. Anti-HAV seroconversion was measured by radioimmunoassay (RIA) and neutralizing antibodies by an antigen reduction assay. After Ig injection (0.06 ml/kg), anti-HAV seroconversion occurred in 100% of recipients at week 1, declining to 10% at week 12 and 0% by week 20. In contrast, after a single 25 ng dose, RIA seropositivity in iHAV vaccinees was 80% by week 2, reaching 100% by week 5 and persisted up to week 24, at which time anti-HAV geometric mean titres (GMT) were two fold higher than those seen at week 1 after Ig. Postbooster anti-HAV titres in iHAV recipients rose within 4 weeks to 73-fold greater than the peak GMT seen one week after Ig, and 400-fold higher than GMT at 12 weeks after Ig. Neutralizing antibody titres after iHAV followed a similar pattern, as observed for anti-HAV. iHAV was well tolerated; placebo and vaccine tolerability were indistinguishable, with no serious adverse experiences observed. In conclusion, active vaccination with a single iHAV dose may eventually replace Ig for pre-exposure prophylaxis.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006506 Hepatitis A INFLAMMATION of the LIVER in humans caused by a member of the HEPATOVIRUS genus, HUMAN HEPATITIS A VIRUS. It can be transmitted through fecal contamination of food or water. Hepatitis, Infectious,Infectious Hepatitis,Hepatitides, Infectious,Infectious Hepatitides
D006507 Hepatovirus A genus of PICORNAVIRIDAE causing infectious hepatitis naturally in humans and experimentally in other primates. It is transmitted through fecal contamination of food or water. HEPATITIS A VIRUS is the type species. Hepatitis Virus, Infectious,Infectious Hepatitis Virus,Hepatitis Viruses, Infectious,Hepatoviruses,Infectious Hepatitis Viruses
D006508 Hepatitis Antibodies Immunoglobulins raised by any form of viral hepatitis; some of these antibodies are used to diagnose the specific kind of hepatitis. Antibodies, Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Tourist hepatitis, antibodies to hepatitis A virus and immune serum globulin prophylaxis.
January 1978, Infection,
D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
[Immune response to one booster dose of inactivated hepatitis A vaccine in college students].
May 2017, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine.
January 2004, Journal of travel medicine,
D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin.
September 1993, The Journal of infectious diseases,
D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine.
January 2002, Scandinavian journal of infectious diseases,
D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Hepatitis A after a single dose of an inactivated hepatitis A vaccine.
January 2002, Scandinavian journal of infectious diseases,
D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Dose response study of an inactivated hepatitis A virus vaccine.
January 1993, Journal of hepatology,
D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin.
July 1997, The Journal of infectious diseases,
D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine.
October 2020, The Journal of infectious diseases,
D Shouval, and Y Ashur, and R Adler, and J A Lewis, and M E Armstrong, and J P Davide, and B McGuire, and B Kuter, and L Brown, and W Miller
Hepatitis A vaccine versus immune globulin for postexposure prophylaxis.
October 2007, The New England journal of medicine,
Copied contents to your clipboard!